"Long-term efficacy and safety of L-glutamine in preventing sickle cell disease-related acute complications and haemolysis in paediatric and adult patients - real-world, observational study".

European Journal of HaematologyVolume 110, Issue 6 p. 772-773 LETTER TO THE EDITOR “Long-term efficacy and safety of L-glutamine in preventing sickle cell disease-related acute complications and hemolysis in pediatric and adult patients—Real-world, observational study” Narcisse Elenga, Narcisse Elenga orcid.org/0000-0003-0624-4180 Centre Hospitalier de Cayenne, Cayenne, FranceSearch for more papers by this authorGylna Loko, Gylna Loko orcid.org/0000-0002-6185-1146 Centre de reference de la drepanocytose, CHU de la Guadeloupe, Pointe-à Pitre, Guadeloupe, FranceSearch for more papers by this authorMaryse Etienne-Julan, Maryse Etienne-Julan orcid.org/0000-0003-1339-6545 Centre de reference de la drepanocytose, CH de Fort de France, Fort-de-France, FranceSearch for more papers by this authorRanda Al-Okka, Randa Al-Okka Department of Pharmacy, NCCCR Pharmacy, Hamad Medical Corporation, Doha, Ad Dawhah, QatarSearch for more papers by this authorAhmad M. Adel, Ahmad M. Adel orcid.org/0000-0001-7858-6951 Department of Pharmacy, NCCCR Pharmacy, Hamad Medical Corporation, Doha, Ad Dawhah, QatarSearch for more papers by this authorMohamed A. Yassin, Corresponding Author Mohamed A. Yassin [email protected] orcid.org/0000-0002-1144-8076 Medical Oncology Department—Hematology Section, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar Correspondence Mohamed A. Yassin, Medical Oncology Department—Hematology Section, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar. Email: [email protected]Search for more papers by this author Narcisse Elenga, Narcisse Elenga orcid.org/0000-0003-0624-4180 Centre Hospitalier de Cayenne, Cayenne, FranceSearch for more papers by this authorGylna Loko, Gylna Loko orcid.org/0000-0002-6185-1146 Centre de reference de la drepanocytose, CHU de la Guadeloupe, Pointe-à Pitre, Guadeloupe, FranceSearch for more papers by this authorMaryse Etienne-Julan, Maryse Etienne-Julan orcid.org/0000-0003-1339-6545 Centre de reference de la drepanocytose, CH de Fort de France, Fort-de-France, FranceSearch for more papers by this authorRanda Al-Okka, Randa Al-Okka Department of Pharmacy, NCCCR Pharmacy, Hamad Medical Corporation, Doha, Ad Dawhah, QatarSearch for more papers by this authorAhmad M. Adel, Ahmad M. Adel orcid.org/0000-0001-7858-6951 Department of Pharmacy, NCCCR Pharmacy, Hamad Medical Corporation, Doha, Ad Dawhah, QatarSearch for more papers by this authorMohamed A. Yassin, Corresponding Author Mohamed A. Yassin [email protected] orcid.org/0000-0002-1144-8076 Medical Oncology Department—Hematology Section, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar Correspondence Mohamed A. Yassin, Medical Oncology Department—Hematology Section, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar. Email: [email protected]Search for more papers by this author First published: 02 February 2023 https://doi.org/10.1111/ejh.13939Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008; 111(1): 402-410. doi:10.1182/blood-2007-04-081703 2Yutaka Niihara STM, Kanter J, Lanzkron S, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018; 379(3): 226-235. 3Narcisse Elenga GL, Etienne-Julan M, Al-Okka R, Adel AM, Yassin MA. Real-world data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. Front Med. 2022; 9. 4Shah NBM, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PLoS One. 2019; 14(7). 5Sins JWRMD, Davis SCAT, Biemond BJ, Fijnvandraat K. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Adv. 2017; 1(19): 1598-1616. Volume110, Issue6June 2023Pages 772-773 ReferencesRelatedInformation